Korean J Anesthesiol.  2008 Jul;55(1):66-71. 10.4097/kjae.2008.55.1.66.

Antiemetic effect of oral ramosetron in women undergoing thyroidectomy

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, Kosin University College of Medicine, Busan, Korea. kshwan@ns.kosinmed.or.kr

Abstract

BACKGROUND: Postoperative nausea and vomiting (PONV) after thyroidectomy in women is especially frequent. Ramosetron and dexamethasone prevent cancer chemotherapy-related nausea and vomiting- and PONV.
METHODS
Ninety three women undergoing thyroidectomy under general anesthesia with sevoflurane and remifentanil were allocated to one of three groups: Control (n = 30), ramosetron (Group R, n = 30), ramosetron with dexamethasone (Group RD, n = 33). Doses of ramosetron (0.1 mg) oral tablet by oral route and intravenous dexamethasone (5 mg) were used. The incidence and severity of PONV, and postoperative blood glucose level in each group were studied.
RESULTS
The incidence of PONV in the control and R and RD groups were 43%, 20%, and 18% respectively. The incidence and severity of PONV were similar in the R and the RD groups. Blood glucose levels postoperatively were higher in RD group compared with control and R groups.
CONCLUSIONS
Oral ramosetron reduced the incidence of postoperative nausea. The combination of ramosetron and dexamethasone increased postoperative blood glucose levels significantly without additional effect on PONV.

Keyword

blood glucose; dexamethasone; postoperative nausea and vomiting; ramosetron P.O.; thyroidectomy

MeSH Terms

Anesthesia, General
Antiemetics
Benzimidazoles
Blood Glucose
Dexamethasone
Female
Glucose
Humans
Incidence
Methyl Ethers
Nausea
Piperidines
Postoperative Nausea and Vomiting
Thyroidectomy
Antiemetics
Benzimidazoles
Blood Glucose
Dexamethasone
Glucose
Methyl Ethers
Piperidines
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr